Fundamentals Hub
KAPA Kairos Pharma, LTD.
KAPA financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 3 annual and 0 of 11 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$6.90M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
818-404-5541
EIN
462993314
Headquarters
LOS ANGELES, CA, 90064
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
▼ Key Metrics (TTM)
As of Jun 30, 2026Financials
Revenue
-
Net Income
$-5.81M
Total Assets
$4.46M
Total Equity
$4.19M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-138.5%
Return on Assets
-130.3%
Current Ratio
11.98x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| OPERATING EXPENSES | |||
| R&D Expense | $2.14M | $414.00K | $82.00K |
| SG&A Expense | $3.44M | $1.93M | $1.63M |
| Operating Income | $-5.57M | $-2.34M | $-1.71M |
| NON-OPERATING INCOME / EXPENSE | |||
| Other Income/Expense | $125.00K | $-260.00K | $-98.00K |
| Net Income | $-5.45M | $-2.60M | $-1.81M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-0.30 | $-0.23 | $-0.17 |
| Diluted Shares | 18.43M | 11.36M | 10.38M |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $4.49M | $1.27M | $93.00K |
| Other Current Assets | $51.00K | $38.00K | $8.00K |
| Current Assets | $5.39M | $4.17M | $101.00K |
| Intangible Assets | $62.00K | $222.00K | $382.00K |
| Noncurrent Assets | $1.15M | $1.60M | $864.00K |
| Total Assets | $6.54M | $5.77M | $965.00K |
| LIABILITIES | |||
| Accounts Payable | $199.00K | $992.00K | $2.40M |
| Current Liabilities | $199.00K | $992.00K | $2.41M |
| Noncurrent Liabilities | - | $0 | $638.00K |
| Total Liabilities | - | $992.00K | $3.04M |
| EQUITY | |||
| Common Stock | $21.00K | $14.00K | $11.00K |
| Additional Paid-in Capital | $20.58M | $13.58M | $4.12M |
| Retained Earnings | $-14.26M | $-8.82M | $-6.21M |
| Total Equity | $6.34M | $4.78M | $-2.08M |
| Total Liabilities & Equity | $6.54M | $5.77M | $965.00K |
| SUPPLEMENTAL | |||
| Shares Outstanding | 20.82M | 13.74M | 10.56M |
| Check: A − (L + E + NCI) | $199.00K | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-3.44M | $-3.96M | $81.00K |
| Capital Expenditures | - | - | - |
| Cash from Investing | - | - | - |
| Cash from Financing | $6.66M | $5.13M | $-425.00K |
| Free Cash Flow | - | - | - |
| Beginning Cash (CFS) | $1.27M | $93.00K | - |
| Net Change in Cash | - | - | - |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | - | - | - |
| Cash per BS | $4.49M | $1.27M | $93.00K |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $4.49M | $1.27M | $93.00K |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is Kairos Pharma, LTD. profitable?
No. Kairos Pharma, LTD. reported $-5.81M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.